[Optimization of treatment of depression with administration of ethylmethylhydroxypyridine succinate (Mexicor)].

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)

Administration of Mexicor together with SSRIs leads to improved efficacy and tolerability of antidepressant therapy, and in the future, Mexicor may be recommended as an adjuvant in SSRI therapy for depression.

Keyphrases

depressive symptoms
sleep quality
major depressive disorder
early stage
open label
current status
clinical trial
combination therapy
mesenchymal stem cells
placebo controlled
replacement therapy
physical activity